EOC
EUROASIAN
ONLINE
CONFERENCES

SPAIN
CONFERENCE

INTERNATIONAL CONFERENCE ON SUPPORT OF MODERN SCIENCE AND INNOVATION

Google Scholar zenodo OpenAIRE doi digital object identifier

INTERNATIONAL CONFERENCE ON SUPPORT OF MOERN SCIENCE AND INNOVATION: a collection scientific works of the International scientific conference – Madrid, Spain, 2026, Issue 3.

Languages of publication: Uzbek**,** English, Russian, German, Italian, Spanish,

The collection consists of scientific research of scientists, graduate students and students who took part in the International Scientific online conference **«INTERNATIONAL CONFERENCE ON SUPPORT OF MOERN SCIENCE AND INNOVATION»**. Which took place in Spain, 2026.

Conference proceedings are recommended for scientists and teachers in higher education establishments. They can be used in education, including the process of post - graduate teaching, preparation for obtain bachelors' and masters' degrees. The review of all articles was accomplished by experts, materials are according to authors copyright. The authors are responsible for content, researches results and errors.



UDC: 616.12-005.4:612.39:579.835

CLINICAL EFFECTIVENESS OF IMPROVING DIAGNOSTIC AND THERAPEUTIC APPROACHES FOR ASSESSING THE METABOLIC ACTIVITY OF THE GUT MICROBIOTA IN PATIENTS WITH ISCHEMIC HEART DISEASE

Ravshanov Abdullajon Shuxrat ogli[1]
Kenjayev Olimjon Obidjonovich[2]
Central Asian Medical University international medical university, Department of Internal Diseases in Family Medicine, 1st-year Clinical Resident, 64 Burhoniddin Marg‘inoniy Street, Fergana City, Uzbekistan, tel.: + Email: abdullajonravshanov34@gmail.com[1], 998 95 485 00 70, e-mail: info@camuf.uz[1]
Central Asian Medical University international medical university, Head of the Department of Internal Diseases in Family Medicine, PhD, 64 Burhoniddin Marg‘inoniy Street, Fergana City, Uzbekistan, tel.: +998 95 485 00 70, e-mail: info@camuf.uz[2]

Abstract: Ischemic heart disease remains one of the leading causes of mortality worldwide and represents a major burden on global healthcare systems. In recent years, increasing attention has been directed toward the role of the intestinal microbiota in cardiovascular pathology. The gut microbiota functions as a complex metabolic organ capable of producing numerous bioactive metabolites that influence systemic inflammation, lipid metabolism, endothelial function, and immune regulation. Alterations in microbial composition and metabolic activity have been associated with the development and progression of ischemic heart disease. Modern research indicates that microbial metabolites such as trimethylamine N-oxide, short-chain fatty acids, and secondary bile acids may significantly contribute to atherosclerotic plaque formation and vascular dysfunction. Consequently, the evaluation of gut microbial metabolic activity has become a promising diagnostic and therapeutic target in cardiology. This article presents a theoretical and analytical overview of modern diagnostic strategies used to assess microbiota metabolism and explores therapeutic interventions aimed at modulating gut microbial activity in patients with ischemic heart disease. The analysis is based on contemporary scientific literature, dissertations, and clinical investigations. Particular attention is given to metabolomic profiling, microbial sequencing technologies, and targeted microbiota modulation strategies. The integration of microbiota-centered diagnostics into cardiological practice may contribute to earlier risk identification and improve individualized therapeutic strategies for patients suffering from ischemic heart disease.

Keywords: gut microbiota, ischemic heart disease, metabolomics, trimethylamine N-oxide, cardiovascular risk, microbial metabolism, atherosclerosis.

Introduction: Ischemic heart disease (IHD) remains one of the most significant causes of morbidity and mortality worldwide. According to global epidemiological assessments, cardiovascular diseases account for approximately 17.9 million deaths annually, and nearly half of these cases are related to ischemic heart disease.

Traditional risk factors such as hypertension, hyperlipidemia, smoking, diabetes mellitus, and sedentary lifestyle have long been considered the primary contributors to the development of coronary artery pathology. However, growing evidence indicates that additional biological systems may influence cardiovascular health and disease progression.

One of the most actively investigated areas in contemporary biomedical science is the relationship between the intestinal microbiota and cardiovascular disorders. The human gastrointestinal tract hosts a complex microbial ecosystem composed of trillions of microorganisms, including bacteria, archaea, viruses, and fungi. These microorganisms participate in numerous metabolic processes, including nutrient digestion, vitamin synthesis, immune system modulation, and production of biologically active metabolites.

Recent advances in molecular biology and high-throughput sequencing technologies have revealed that gut microbiota exerts significant systemic effects through its metabolic activity. Microbial metabolites can enter the bloodstream and interact with host metabolic pathways, thereby influencing lipid metabolism, inflammatory signaling, endothelial function, and vascular homeostasis. Disturbances in microbial composition, commonly referred to as dysbiosis, have been associated with metabolic disorders, obesity, diabetes, and cardiovascular diseases.

Among the metabolites produced by intestinal bacteria, trimethylamine N-oxide (TMAO) has attracted particular scientific interest. Elevated plasma concentrations of this compound have been linked with increased risk of atherosclerosis, thrombosis, and cardiovascular mortality. Studies have shown that patients with higher circulating TMAO levels demonstrate significantly greater risk of adverse cardiovascular events.

Despite the growing body of evidence linking microbiota metabolism to cardiovascular disease, the diagnostic and therapeutic application of these findings remains insufficiently developed. The assessment of microbial metabolic activity through modern metabolomic and microbiome analysis methods may provide new opportunities for early detection of cardiovascular risk and individualized treatment strategies. Therefore, the aim of this study is to analyze modern diagnostic and therapeutic approaches for evaluating the metabolic activity of the gut microbiota in patients with ischemic heart disease and to highlight their potential clinical significance.

Literature Review: Scientific interest in the interaction between gut microbiota and cardiovascular diseases has grown rapidly over the last decade. Numerous experimental and clinical investigations have demonstrated that intestinal microorganisms influence host metabolism through complex biochemical pathways. The gut microbiota is now widely recognized as a metabolic organ capable of producing thousands of bioactive molecules that regulate physiological processes far beyond the gastrointestinal tract. Early microbiological research primarily focused on identifying microbial species present in the human intestine.

However, modern studies emphasize functional activity rather than simple microbial composition. This shift occurred due to the development of advanced analytical technologies such as metagenomic sequencing, metabolomics, and metatranscriptomics. These methods allow researchers to investigate microbial metabolic products and their systemic effects on the host organism.

One of the most widely studied metabolic pathways involves the microbial conversion of dietary nutrients such as choline, L-carnitine, and phosphatidylcholine into trimethylamine. After absorption into the bloodstream, trimethylamine is converted in the liver into trimethylamine N-oxide. Elevated plasma levels of this compound have been associated with increased risk of atherosclerotic plaque formation, endothelial dysfunction, and thrombosis.

Several large clinical studies have demonstrated that patients with higher circulating levels of microbial metabolites exhibit a significantly increased risk of major cardiovascular events. In some investigations, elevated trimethylamine N-oxide concentrations were associated with a two- to three-fold increase in the likelihood of myocardial infarction, stroke, or cardiovascular death.

In addition to trimethylamine N-oxide, short-chain fatty acids produced during microbial fermentation of dietary fiber play an important role in host metabolism. Compounds such as acetate, propionate, and butyrate participate in regulation of glucose metabolism, lipid synthesis, and immune system activity. These metabolites are generally considered beneficial because they support intestinal barrier function and exert anti-inflammatory effects.

The relationship between gut microbiota and ischemic heart disease has also been investigated in animal models. Experimental studies involving germ-free mice have demonstrated that transplantation of microbiota from animals with atherosclerosis can accelerate plaque formation in previously healthy recipients. These findings suggest that microbial metabolic activity may directly contribute to cardiovascular pathology.

Recent literature also highlights the potential of microbiota-targeted therapies. Dietary interventions, probiotic supplementation, prebiotic compounds, and microbial enzyme inhibitors have all been investigated as strategies for modulating microbial metabolism. These approaches aim to reduce the production of harmful metabolites while enhancing beneficial microbial functions. Overall, the available scientific evidence indicates that the metabolic activity of the gut microbiota represents a significant but previously underestimated factor in the development of ischemic heart disease. Continued research is necessary to translate these discoveries into practical diagnostic and therapeutic tools.

Results: Analysis of contemporary scientific publications, clinical investigations, and doctoral research demonstrates a growing body of evidence supporting the involvement of gut microbiota metabolism in the pathogenesis of ischemic heart disease. Studies conducted across different populations consistently report significant associations between microbial metabolic activity and cardiovascular risk indicators. One of the most extensively studied biomarkers is trimethylamine

N-oxide. Clinical investigations involving large patient cohorts have demonstrated that individuals with elevated plasma concentrations of this metabolite have a markedly increased probability of developing cardiovascular complications. In several prospective studies involving more than 4,000 participants, patients in the highest quartile of trimethylamine N-oxide concentration exhibited approximately 2.5 times higher risk of myocardial infarction and stroke compared with those in the lowest quartile.

Metabolomic analyses have revealed that patients with ischemic heart disease often demonstrate characteristic metabolic signatures associated with altered microbial activity. These metabolic patterns include increased levels of trimethylamine derivatives, changes in bile acid metabolism, and alterations in short-chain fatty acid profiles. Such metabolic disturbances are believed to contribute to chronic inflammation, oxidative stress, and endothelial dysfunction.

Advanced sequencing studies have also identified differences in microbial composition between healthy individuals and patients with coronary artery disease. Reduced diversity of beneficial bacterial species and increased abundance of pro-inflammatory microorganisms have been observed in many clinical investigations. These microbial changes are frequently accompanied by increased production of metabolites that promote atherosclerotic processes.

Statistical analyses from international cardiovascular registries indicate that gut microbiota–related metabolic markers may significantly improve cardiovascular risk prediction models. When microbial metabolite measurements are added to traditional risk assessment parameters, predictive accuracy for major adverse cardiovascular events increases substantially. In some models, risk prediction improvement exceeds 20 percent compared with traditional biomarkers alone.

Research involving interventional strategies further supports the clinical relevance of microbial metabolism in ischemic heart disease. Several clinical trials investigating dietary fiber supplementation have demonstrated improvements in lipid profiles, inflammatory markers, and endothelial function. These beneficial effects are believed to result from increased production of short-chain fatty acids by intestinal bacteria.

Probiotic interventions have also shown promising results. Studies involving supplementation with specific bacterial strains have reported reductions in inflammatory cytokines and improvements in metabolic parameters. Some investigations have documented modest reductions in low-density lipoprotein cholesterol levels following long-term probiotic administration. Another promising area involves pharmacological inhibition of microbial enzymes responsible for trimethylamine production. Experimental compounds targeting microbial trimethylamine lyases have demonstrated the ability to significantly reduce circulating trimethylamine N-oxide levels in animal models without disrupting overall microbial community structure.

Collectively, these findings indicate that the metabolic activity of the gut microbiota plays an important role in cardiovascular disease progression.

Diagnostic evaluation of microbial metabolites and targeted modulation of microbiota metabolism may therefore represent valuable strategies for improving prevention and treatment of ischemic heart disease.

Discussion: The growing recognition of the gut microbiota as a metabolically active organ has significantly expanded the understanding of cardiovascular disease pathogenesis. Traditional models of ischemic heart disease primarily focused on lipid accumulation, endothelial injury, and inflammatory processes as the main drivers of atherosclerosis. While these mechanisms remain central to disease development, recent research suggests that microbial metabolism may influence many of these pathways simultaneously.

One of the most compelling aspects of microbiota research is the ability of microbial metabolites to act as systemic signaling molecules. Compounds produced within the intestinal lumen can enter the bloodstream and interact with distant organs, including the cardiovascular system. This phenomenon provides a mechanistic explanation for how gastrointestinal microorganisms can influence vascular health. The metabolite trimethylamine N-oxide has emerged as a particularly important link between diet, microbiota, and cardiovascular disease. Dietary nutrients rich in choline and L-carnitine are metabolized by intestinal bacteria into trimethylamine, which is subsequently converted into trimethylamine N-oxide in the liver.

Elevated concentrations of this compound have been associated with enhanced platelet activation, impaired cholesterol metabolism, and acceleration of atherosclerotic plaque development. The clinical significance of these findings lies in the possibility of identifying new diagnostic biomarkers. Measurement of microbial metabolites in blood plasma may allow clinicians to detect early metabolic disturbances before the appearance of advanced cardiovascular pathology. This approach could complement existing diagnostic methods such as lipid profiling and inflammatory marker assessment. Another important implication involves the development of microbiota-targeted therapeutic strategies. Unlike many genetic risk factors, the composition and metabolic activity of the gut microbiota can be modified through lifestyle interventions, diet, and pharmacological treatments. This modifiability makes the microbiome an attractive target for preventive cardiology.

Dietary modification represents one of the simplest and most accessible strategies for influencing microbial metabolism. Diets rich in dietary fiber promote the growth of beneficial bacterial species that produce short-chain fatty acids. These metabolites have been shown to reduce systemic inflammation, improve insulin sensitivity, and support vascular health. Conversely, diets high in processed meat and animal-derived nutrients may increase production of trimethylamine N-oxide.

Probiotic and prebiotic interventions also demonstrate potential therapeutic benefits. By selectively stimulating beneficial microbial species, these strategies may shift metabolic pathways toward production of protective metabolites.

However, the clinical effectiveness of such interventions remains variable and may depend on individual microbiome composition.

Pharmacological approaches targeting microbial metabolic enzymes represent another promising direction. Selective inhibition of bacterial trimethylamine production may reduce cardiovascular risk without eliminating beneficial microbial functions. Such strategies are currently under active investigation in experimental and early clinical studies.

Despite significant progress in this field, several challenges remain. The gut microbiota is an extremely complex ecosystem influenced by genetics, diet, environment, and lifestyle factors. As a result, identifying universal microbial biomarkers applicable to all populations may be difficult. Furthermore, long-term clinical trials are required to confirm whether microbiota-targeted therapies can effectively reduce cardiovascular mortality. Nevertheless, the integration of microbiome science into cardiovascular research represents an important step toward more personalized and preventive approaches in modern medicine.

Conclusion: The metabolic activity of the gut microbiota represents an important and emerging factor in the pathogenesis of ischemic heart disease. Contemporary scientific evidence demonstrates that microbial metabolites can significantly influence lipid metabolism, inflammatory responses, endothelial function, and atherosclerotic plaque development. Diagnostic assessment of these metabolic products provides promising opportunities for early identification of cardiovascular risk and improved patient stratification. Advances in metabolomic analysis and microbiome sequencing technologies have made it possible to investigate microbial metabolism with increasing precision. These tools may contribute to the development of personalized diagnostic strategies and targeted therapeutic interventions. Modulation of gut microbiota through dietary interventions, probiotics, and pharmacological inhibitors represents a promising direction for future cardiovascular prevention and treatment. Continued interdisciplinary research integrating cardiology, microbiology, and metabolic science is essential for translating these discoveries into effective clinical practice.

References:

1. Brown, J. M., & Hazen, S. L. (2018). Microbial modulation of cardiovascular disease. Nature Reviews Microbiology.
2. Tang, W. H. W., Kitai, T., & Hazen, S. L. (2017). Gut microbiota in cardiovascular health and disease. Circulation Research.
3. Wang, Z., et al. (2019). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature.
4. Koeth, R. A., et al. (2018). Intestinal microbiota metabolism of L-carnitine and cardiovascular risk. Nature Medicine.
5. Zhu, W., et al. (2020). Gut microbial metabolite TMAO in cardiovascular disease. Journal of the American College of Cardiology.
6. Jie, Z., et al. (2017). The gut microbiome in atherosclerotic cardiovascular disease. Nature Communications.
7. Tilg, H., & Moschen, A. R. (2019). Microbiota and cardiovascular disease. Gut.